Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Monroeville, Pennsylvania Clinical Trials

A listing of Monroeville, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (48) clinical trials

Brentuximab Vedotin for Systemic Sclerosis

This is a multicenter prospective double blind placebo controlled dose escalation safety clinical trial with brentuximab vedotin and stable background immunosuppressive therapy in adult individuals with Diffuse Cutaneous Systemic Sclerosis (dcSSc). Adult male and female participants with dcSSc will be recruited by a collaborative group of clinical sites in the …

Phase

8.32 miles

Learn More »

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung …

Phase

9.07 miles

Learn More »

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

CONSORTIUM-IO is a first-in-human multicenter, open-label study, where it's main objectives will evaluate: Safety and tolerability of VE800 in combination with Nivolumab Efficacy as measured by a total of overall response rate. The study will enroll approximately 111 patients with melanoma, patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma, and patients with …

Phase

9.07 miles

Learn More »

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

PRIMARY OBJECTIVES: (Phase I) I. Determine the safety and tolerability of the combination of PARP inhibitor BGB-290 (BGB-290) and temozolomide (TMZ) in patients with recurrent IDH1/2 mutant glioma, including the maximum tolerated dose (MTD) and characterization of dose-limiting toxicities (DLTs) in the Phase I portion. (Phase II) II. Determine the …

Phase

9.07 miles

Learn More »

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

This is a multicenter, non-randomized, open-label Phase 1b/2 study designed to evaluate safety and tolerability and preliminary efficacy of duvelisib in combination with pembrolizumab in subjects with R/M HNSCC who are eligible for pembrolizumab monotherapy based on the current pembrolizumab prescribing information.

Phase

9.07 miles

Learn More »

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Please Note : This study will be moving from the Phase I portion of the study into the Phase II portion of the study with an Anticipated start date of March 1, 2020. The main goal of this research study is to determine if intraperitoneal (IP) administration of cisplatin in …

Phase

9.07 miles

Learn More »

This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2). Two treatment groups (Group A and Group B) will be evaluated. Part 1a utilizes a 3+3 design to evaluate pembrolizumab …

Phase

9.07 miles

Learn More »

Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Phase 1b To determine the dose of vorinostat that can be safely combined with gemcitabine and docetaxel in patients with advanced sarcomas. To characterize the Pharmacokinetics (PK) and Pharmacodynamics (PD) of vorinostat when combined with gemcitabine and docetaxel in patients with advanced sarcomas. Phase 2 To determine the safety and …

Phase

9.07 miles

Learn More »

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

This is an open-label, multicenter, 2-part trial beginning with a Phase 1b part designed to evaluate the safety and tolerability of Sym004 in combination with nivolumab, followed by a randomized, Phase 2b part designed to evaluate the antitumor effects of Sym004 in combination with nivolumab as compared to nivolumab monotherapy …

Phase

9.07 miles

Learn More »

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the safe dose of olaparib with ramucirumab, but not to exceed olaparib dose of 300 mg twice daily (tablet formulation). (Phase I) II. To determine the efficacy of olaparib plus ramucirumab as measured by the objective response rates (ORR) stratified by BROCA-HR biomarker status. (Phase …

Phase

9.07 miles

Learn More »